期刊
CANCER GENE THERAPY
卷 29, 期 11, 页码 1662-1675出版社
SPRINGERNATURE
DOI: 10.1038/s41417-022-00485-y
关键词
-
类别
资金
- Roswell Park Health Research Incorporated (HRI) Start-Up Funds [714084-01]
- National Cancer Institute (NCI) of the National Institutes of Health (NIH) [R21CA235305]
- National Science Foundation [CBET-1337860]
- National Cancer Institute (NCI) [R01 CA207504]
- NIH [R34 GM134794, R01 GM130915]
- NIH National Cancer Institute Cancer Center Support Grant [CA076056]
- [R01AI140736]
- [P01HL51333]
Our study found that extracellular ST6GAL1 can compensate for insufficient cellular ST6GAL1, promoting cancer cell proliferation and invasiveness. Moreover, we identified novel cofactors in the exosome-like particles that amplify the action of extrinsic ST6GAL1. Overall, this study reveals the importance of ST6GAL1 in tumor pathobiology.
The sialyltransferase ST6GAL1 that adds alpha 2-6 linked sialic acids to N-glycans of cell surface and secreted glycoproteins is prominently associated with many human cancers. Tumor-native ST6GAL1 promotes tumor cell behaviors such as invasion and resistance to cell stress and chemo- and radio-treatments. Canonically, ST6GAL1 resides in the intracellular secretory apparatus and glycosylates nascent glycoproteins in biosynthetic transit. However, ST6GAL1 is also released into the extracellular milieu and extracellularly remodels cell surface and secreted glycans. The impact of this non-canonical extrinsic mechanism of ST6GAL1 on tumor cell pathobiology is not known. We hypothesize that ST6GAL1 action is the combined effect of natively expressed sialyltransferase acting cell-autonomously within the ER-Golgi complex and sialyltransferase from extracellular origins acting extrinsically to remodel cell-surface glycans. We found that shRNA knockdown of intrinsic ST6GAL1 expression resulted in decreased ST6GAL1 cargo in the exosome-like vesicles as well as decreased breast tumor cell growth and invasive behavior in 3D in vitro cultures. Extracellular ST6GAL1, present in cancer exosomes or the freely soluble recombinant sialyltransferase, compensates for insufficient intrinsic ST6GAL1 by boosting cancer cell proliferation and increasing invasiveness. Moreover, we present evidence supporting the existence novel but yet uncharacterized cofactors in the exosome-like particles that potently amplify extrinsic ST6GAL1 action, highlighting a previously unknown mechanism linking this enzyme and cancer pathobiology. Our data indicate that extracellular ST6GAL1 from remote sources can compensate for cellular ST6GAL1-mediated aggressive tumor cell proliferation and invasive behavior and has great clinical potential for extracellular ST6GAL1 as these molecules are in the extracellular space should be easily accessible targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据